Xuyang Song

Xuyang Song

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4455504
-
person_outline Xuyang Song's MOST POPULAR ARTICLES
1-) 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I … Journal of Thoracic Oncology 11 (4), S79, 2016
2-) Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status Clinical Pharmacology & Therapeutics 103 (4), 631-642, 2018
3-) Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort European journal of cancer 109, 154-161, 2019
4-) First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer J Clin Oncol 36 (15_suppl), 3540, 2018
5-) Applications of model-based meta-analysis in drug development Pharmaceutical research 39 (8), 1761-1777, 2022